NFKBIE
NFKBIE (NF-kappa-B inhibitor epsilon) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.
Overview
Sequesters NF-kappa-B transcription factor complexes in the cytoplasm, thereby inhibiting their activity. Sequestered complexes include NFKB1-RELA (p50-p65) and NFKB1-REL (p50-c-Rel) complexes. Limits B-cell activation in response to pathogens, and also plays an important role in B-cell development.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.72, genetic association 0.00, somatic mutation 0.81). IntOGen calls it a driver in 7 cohorts (3 activating, 4 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Lung Adenocarcinoma, Malignant Lymphoma, Non-Hodgkin Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NFKBIE (NF-kappa-B inhibitor epsilon) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.
- 1 · What it is
NFKBIE (NF-kappa-B inhibitor epsilon) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.
- 2 · What goes wrong in cancer
Sequesters NF-kappa-B transcription factor complexes in the cytoplasm, thereby inhibiting their activity. Sequestered complexes include NFKB1-RELA (p50-p65) and NFKB1-REL (p50-c-Rel) complexes.
- 3 · How drugs use it
No product in this corpus aims at NFKBIE yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:7799 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O00221 (protein name, function text, keywords and locations (REST API)); CIViC gene NFKBIE (2 evidence items, 0 assertions, 1 variants; diseases: Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000146232 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: melanoma 0.55, acute lymphoblastic leukaemia 0.54, diffuse large B-cell lymphoma 0.53, non-Hodgkin lymphoma 0.68, skin cancer 0.56, leukaemia 0.62 (GraphQL API, CC0)); IntOGen NFKBIE (driver in 7 cohorts (Act 3, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Sequesters NF-kappa-B transcription factor complexes in the cytoplasm, thereby inhibiting their activity. Sequestered complexes include NFKB1-RELA (p50-p65) and NFKB1-REL (p50-c-Rel) complexes. Limits B-cell activation in response to pathogens, and also plays an important role in B-cell development. Location: Cytoplasm (UniProt). Locus 6p21.1 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.68 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Leukaemia: Open Targets association 0.62 with leukaemia (MONDO_0005059)
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Diffuse large B-cell lymphoma: Open Targets association 0.53 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease
- Mantle cell lymphoma: CIViC evidence names this disease
- Chronic lymphocytic leukaemia: IntOGen driver in 2 cohorts (CLLSLL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NFKBIE" OR ABSTRACT:"NFKBIE" OR TITLE:"NFKB inhibitor epsilon" OR ABSTRACT:"NFKB inhibitor epsilon" OR TITLE:"NF-kappa-B inhibitor epsilon" OR ABSTRACT:"NF-kappa-B inhibitor epsilon") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NFKBIE, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetBIRC3
Shares Mantle cell lymphoma, Leukaemia (all types), Chronic lymphocytic leukaemia, Skin cancer (all types).
- TargetPOT1
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetTNFAIP3
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetCNOT3
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetMEF2B
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetFAS
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetCCND3
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetPAX5
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.